How to buy BriaCell Therapeutics stock (BriaCell Therapeutics)

BriaCell Therapeutics is a biotechnology business based in the US. BriaCell Therapeutics shares (BCTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.56 – a decrease of 0.93% over the previous week.

Our top picks for where to buy Briacell Therapeutics stock

Buy BriaCell Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

BriaCell Therapeutics stock price (NASDAQ: BCTX)

Use our graph to track the performance of BCTX stocks over time.

BriaCell Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.56
52-week range	$0.46 - $5.97
50-day moving average more info button	$0.78
200-day moving average more info button	$1.26
Wall St. target price	$15.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.89

Is it a good time to buy BriaCell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BriaCell Therapeutics price performance over time

Historical closes compared with the close of $0.535 from 2024-12-26

1 week (2024-12-20)	-4.63%
1 month (2024-11-27)	-36.48%
3 months (2024-09-27)	-39.29%
6 months (2024-06-28)	-53.07%

1 year (2023-12-28)	-90.22%
2 years (2022-12-28)	-88.11%
3 years (2021-12-28)	8.4185
5 years (2019-12-27)	9.6565

BriaCell Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-126.11%
Return on equity TTM	-206.01%
Profit margin	0%
Book value	$-0.13
Market Capitalization more info button	$23.7 million

TTM: trailing 12 months

BriaCell Therapeutics share dividends

We're not expecting BriaCell Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Amgen (AMGN.US) (3.61% forward annual dividend yield)

Have BriaCell Therapeutics's shares ever split?

BriaCell Therapeutics's shares were split on a 1:300 basis on 1 January 2020 . So if you had owned 300 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BriaCell Therapeutics shares – just the quantity. However, indirectly, the new 29900% higher share price could have impacted the market appetite for BriaCell Therapeutics shares which in turn could have impacted BriaCell Therapeutics's share price.

BriaCell Therapeutics share price volatility

Over the last 12 months, BriaCell Therapeutics's shares have ranged in value from as little as $0.4641 up to $5.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BriaCell Therapeutics's is 1.816. This would suggest that BriaCell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put BriaCell Therapeutics's beta into context you can compare it against those of similar companies.

• Amgen (AMGN.US): 0.599
• BeiGene (BGNE.US): 0.63
• Corcept Therapeutics Incorporated (CORT.US): 0.455

BriaCell Therapeutics overview

BriaCell Therapeutics Corp. , a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Frequently asked questions

null
What percentage of BriaCell Therapeutics is owned by insiders or institutions?
Currently 14.332% of BriaCell Therapeutics shares are held by insiders and 4.646% by institutions. When does the fiscal year end for BriaCell Therapeutics?
BriaCell Therapeutics's fiscal year ends in July. Where is BriaCell Therapeutics based?
BriaCell Therapeutics's address is: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 What is BriaCell Therapeutics's ISIN number?
BriaCell Therapeutics's international securities identification number is: CA10778Y3023